Archive

PROJECT SUMMARY: Dystonia is a disabling neurological condition that is relatively common. Primary dystonia has a prevalence of greater that 3/1000 people. This extrapolates to 70.000 people in Australia. Dystonia secondary to other neurological disease such as stroke or neurodegenerative disease is probably even more common....

PROJECT SUMMARY: The aim of this project is explore the therapeutic potential of progranulin - a secreted protein that has recently been linked to dementia - for the acute treatment of stroke. We hypothesise that treatment with progranulin will reduce brain damage and improve outcome when...

PROJECT SUMMARY: A common, life-threatening complication of stroke is cerebral oedema (brain swelling) and subsequent elevated intracranial pressure (ICP). Stroke patients suffering this condition are more likely to die or be left permanently disabled as a result. Despite this, current treatments for cerebral oedema and elevated...

Glioblastoma multiforme (GBM) is the most common and most deadly form of primary brain cancer. Most patients survive only 12 months from diagnosis, often with significant disability. Despite a huge volume of research into the disease, only two drugs have shown significant benefit in clinical...

PROJECT SUMMARY: Glioblastoma (GBM) is a devastating primary brain cancer that affects around 800 Australians annually. Despite surgery, radiotherapy and chemotherapy, 1 in 2 people diagnosed with GBM will not survive for more than 14 months. The short life expectancy among patients highlights the need for...

PROJECT SUMMARY: Traumatic brain injury (TBI) remains one of the leading causes of death, disability, and hospitalization worldwide. TBI has a significant burden of disease within Australia, with TBI-related costs estimated to total $8.6 billion, annually. These costs include rehabilitation services, loss of productivity, and requirements...

PROJECT SUMMARY: Both neuropathic pain and epilepsy are common chronic disorders which result in significant morbidity to the sufferer, and have a major impact on health resources. Severe chronic pain costs the Australian economy $34 billion per year, and may carry a global health impact equivalent...

Elizabeth Penfold Simpson Award ~ On behalf of: Wai Khay Leong, Tanya L. Henshall, Agnes Arthur, Karlea L. Kremer, Martin D. Lewis, Stephen C. Helps, John Field, Monica A. Hamilton-Bruce, Scott Warming, Jim Manavis, Robert Vink, Stan Gronthos, Simon A. Koblar Human adult dental pulp stem cells...

PROJECT SUMMARY: Alzheimer’s disease is the most common form of dementia and its prevalence in Australia is increasing at a rapid rate. By 2050, Alzheimer’s disease is predicted to be the most costly health problem in the country. This imminent epidemic can only be prevented with...

PROJECT SUMMARY: Alzheimer’s disease (AD) is a progressive degenerative condition which develops over several decades. Symptoms include decline in memory and thinking (cognitive) abilities which are sufficient to interfere with everyday activities. The greatest known risk factor for AD is advancing age. The world’s population is growing...

PROJECT SUMMARY: Alpha(α)-synuclein is a key protein in Parkinson’s Disease (PD). It is the predominant component of Lewy bodies, which are a hallmark of the pathology of PD and related neurodegenerative disorders. Thus, something must be going wrong with α-synuclein, but it has been difficult to...

PROJECT SUMMARY: Despite dramatic advances in technologies, accurate diagnosis of dementia remains a scientific challenge, particularly in the early stages of disease. The clinical diagnosis in a person suspected of suffering dementia still relies on observation of changes in behaviour, particularly changes in cognitive functions such...

Brain FoundationThe Brain Foundation is the largest, independent funder of brain and spinal injury research in Australia. We believe research is the pathway to recovery.
PLEASE HELP US BY DONATING TO OUR RESEARCH PROGRAM.